- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00033384
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
A Multicenter Phase 2 Study of CI-1040 In Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer Or Pancreatic Cancer
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
- Determine the antitumor activity of CI-1040 in patients with non-small cell lung, breast, colon, or pancreatic cancer.
- Determine the safety profile of this drug in these patients.
- Assess quality of life (overall and for each tumor type) of patients treated with this drug.
- Determine the relationship between study drug concentration and antitumor response in these patients and target suppression and safety of this drug.
- Correlate target suppression (pERK) with antitumor effects of this drug in these patients.
- Correlate the mRNA expression profile of the tumors with antitumor effects of this drug in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to tumor type (non-small cell lung vs breast vs colon vs pancreas).
Patients receive oral CI-1040 twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and then every 28 days during the first 6 months of study therapy.
Patients are followed every 2 months.
PROJECTED ACCRUAL: A total of 52-172 patients (13-43 per stratum) will be accrued for this study.
Undersøgelsestype
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed metastatic or inoperable non-small cell lung, breast, or colon cancer or duct cell carcinoma of the exocrine pancreas
Bidimensionally measurable lesions that are not previously irradiated
- New lesions that have developed in a previously irradiated field may be used as measurable disease
No brain metastases
- Patients with prior brain metastases are allowed provided they have undergone prior resection of metastases and/or 1 prior course of cranial irradiation, have no new sites of brain metastases since then, have no worsening CNS symptoms, and have discontinued prior corticosteroids for at least 30 days
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Sex:
- Not specified
Menopausal status:
- Not specified
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- AST or ALT no greater than 2 times ULN (5 times ULN if due to liver involvement)
Renal:
- Creatinine no greater than 1.5 times ULN
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study participation
- Capable of swallowing intact study medication capsules
- Capable of following instructions regarding study medication or has daily caregiver to administer study medication
- No concurrent serious infection
- No life-threatening illness unrelated to tumor
- No other prior or concurrent malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 2 weeks since prior immunotherapy or biologic therapy
Chemotherapy:
- At least 4 weeks since prior cytotoxic chemotherapy
- No more than 1 prior cytotoxic chemotherapy regimen for metastatic non-small cell lung or colon cancer
- No more than 2 prior cytotoxic chemotherapy regimens for breast cancer
- No prior cytotoxic chemotherapy for pancreatic cancer
Endocrine therapy:
- See Disease Characteristics
- At least 2 weeks since other prior hormonal therapy
Radiotherapy:
- See Disease Characteristics
- At least 3 weeks since prior radiotherapy and recovered
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
Other:
- No other concurrent anticancer agents
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: John J. Rinehart, MD, University of Alabama at Birmingham
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- stadium IV brystkræft
- stadium IIIA brystkræft
- tilbagevendende brystkræft
- stadium IIIB brystkræft
- tilbagevendende ikke-småcellet lungekræft
- fase IIIA ikke-småcellet lungekræft
- stadium IIIB ikke-småcellet lungekræft
- fase IV ikke-småcellet lungekræft
- stadium IV tyktarmskræft
- tilbagevendende tyktarmskræft
- tilbagevendende kræft i bugspytkirtlen
- stadium III tyktarmskræft
- fase IV kræft i bugspytkirtlen
- fase III kræft i bugspytkirtlen
- kanalcelleadenokarcinom i bugspytkirtlen
- fase II kræft i bugspytkirtlen
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Hudsygdomme
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Sygdomme i det endokrine system
- Neoplasmer i fordøjelsessystemet
- Neoplasmer i endokrine kirtler
- Brystsygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Pancreassygdomme
- Brystneoplasmer
- Lungeneoplasmer
- Bugspytkirtel neoplasmer
Andre undersøgelses-id-numre
- CDR0000069279
- UAB-0152
- PFIZER-1040-002-004
- UAB-F011203011
- NCI-G02-2052
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
The First Affiliated Hospital of Xiamen UniversityIkke rekrutterer endnuLocally Advanced Breast Cancer (LABC)
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Beijing Bio-Targeting Therapeutics Technology Co...Trukket tilbage
-
Indonesia UniversityIkke rekrutterer endnuPræhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)Indonesien
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
Atlas UniversityIkke rekrutterer endnuBrystkræft | Locally Advanced Breast Cancer (LABC)Tyrkiet (Türkiye)
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTNBC, Triple Negative Breast CancerKina
Kliniske forsøg med CI-1040
-
PfizerAfsluttetBrystneoplasmer | Karcinom, ikke-småcellet lunge | Kolorektale neoplasmer | Bugspytkirtel neoplasmerForenede Stater
-
BioLineRx, Ltd.Sheba Medical CenterUkendt
-
Superior UniversityAktiv, ikke rekrutterende
-
Universitair Ziekenhuis BrusselRekrutteringSensorineuralt høretab | Cochleære implantaterBelgien
-
HealthPartners InstituteNational Institute on Aging (NIA); OCHIN, Inc.AfsluttetKognitiv svækkelse | DemensForenede Stater
-
Ohio State UniversityUniversity of Missouri-Columbia; University of Alabama at Birmingham; University... og andre samarbejdspartnereAfsluttetSlag | HemipareseForenede Stater
-
University of MiamiCochlearAfsluttet
-
Taipei Medical University HospitalAfsluttet
-
Matthew Bush, MDAfsluttetHøretab | HørelidelserForenede Stater
-
Ohio State UniversityAfsluttetSlag | HemipareseForenede Stater